Conditions: Carcinoma Adenocarcinoma Renal Cell Nephroid Carcinoma Hypernephroid
Keywords: Renal cell carcinoma Adults Bevacizumab RAD001 Everolimus Interferon Clear Roferon Avastin Nephrectomy newly diagnosed
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 365
Healthy volunteers: no

Brief summary:
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.

Detailed description:

Arms:
arm 1: Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks arm 2: Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks

Interventions: intervention 1: RAD001(everolimus) intervention 2: interferon alfa-2a intervention 3: bevacizumab
Intervention descriptions: intervention 1: 10 mg qd intervention 2: dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 intervention 3: 10 mg/kg every 2 weeks

Protocol document: